Xigris Cmte. Invokes History Of Sepsis Failures; "Do It Right," Chair Says
Executive Summary
FDA and Lilly should not miss the opportunity to demonstrate unequivocally the efficacy of a sepsis product, FDA's Anti-Infective Drugs Advisory Committee Chair Barth Reller, MD, Duke University, said during the committee's review of Xigris Oct. 16.
You may also be interested in...
Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients
Xigris, if approved, should be restricted to those severe sepsis patients defined by exclusion criteria in Lilly's pivotal trial, FDA's Anti-Infective Drug Advisory Committee recommended Oct. 16.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials